JANX vs. IDYA, XENE, ARWR, FOLD, HCM, PBH, RARE, MRUS, ACAD, and MLTX
Should you be buying Janux Therapeutics stock or one of its competitors? The main competitors of Janux Therapeutics include IDEAYA Biosciences (IDYA), Xenon Pharmaceuticals (XENE), Arrowhead Pharmaceuticals (ARWR), Amicus Therapeutics (FOLD), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Ultragenyx Pharmaceutical (RARE), Merus (MRUS), ACADIA Pharmaceuticals (ACAD), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical preparations" industry.
IDEAYA Biosciences (NASDAQ:IDYA) and Janux Therapeutics (NASDAQ:JANX) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.
IDEAYA Biosciences has a net margin of -483.05% compared to IDEAYA Biosciences' net margin of -762.92%. IDEAYA Biosciences' return on equity of -13.49% beat Janux Therapeutics' return on equity.
IDEAYA Biosciences presently has a consensus target price of $47.50, suggesting a potential upside of 15.38%. Janux Therapeutics has a consensus target price of $64.83, suggesting a potential upside of 32.53%. Given IDEAYA Biosciences' higher probable upside, analysts plainly believe Janux Therapeutics is more favorable than IDEAYA Biosciences.
In the previous week, IDEAYA Biosciences had 13 more articles in the media than Janux Therapeutics. MarketBeat recorded 30 mentions for IDEAYA Biosciences and 17 mentions for Janux Therapeutics. IDEAYA Biosciences' average media sentiment score of 0.43 beat Janux Therapeutics' score of 0.35 indicating that Janux Therapeutics is being referred to more favorably in the news media.
IDEAYA Biosciences has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500. Comparatively, Janux Therapeutics has a beta of 3.87, indicating that its share price is 287% more volatile than the S&P 500.
98.3% of IDEAYA Biosciences shares are held by institutional investors. Comparatively, 75.4% of Janux Therapeutics shares are held by institutional investors. 3.5% of IDEAYA Biosciences shares are held by company insiders. Comparatively, 35.4% of Janux Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
IDEAYA Biosciences received 91 more outperform votes than Janux Therapeutics when rated by MarketBeat users. Likewise, 67.66% of users gave IDEAYA Biosciences an outperform vote while only 61.11% of users gave Janux Therapeutics an outperform vote.
Janux Therapeutics has lower revenue, but higher earnings than IDEAYA Biosciences. Janux Therapeutics is trading at a lower price-to-earnings ratio than IDEAYA Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Janux Therapeutics beats IDEAYA Biosciences on 9 of the 17 factors compared between the two stocks.
Get Janux Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JANX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Janux Therapeutics Competitors List
Related Companies and Tools
